<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335254</url>
  </required_header>
  <id_info>
    <org_study_id>TT-018</org_study_id>
    <nct_id>NCT03335254</nct_id>
  </id_info>
  <brief_title>A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males</brief_title>
  <official_title>A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TesoRx Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TesoRx Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a phase 1/2a, open-label, single-center study with 3 periods. The aims of the
      study are to:

        1. evaluate the dose-response curve following ascending single doses of TSX-011;

        2. confirm optimum dosing conditions;

        3. evaluate the efficacy of single or multiple daily adaptive dosing; and

        4. evaluate the safety and tolerability of TSX-011.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase 1/2a, open-label, single-center study with 3 periods. The aims of the
      study are to: 1) evaluate the dose-response curve following ascending single doses of
      TSX-011; 2) confirm optimum dosing conditions; 3) evaluate the efficacy of single or multiple
      daily adaptive dosing; and 4) evaluate the safety and tolerability of TSX-011. Up to 24
      hypogonadal men will be enrolled in this study to yield 16 evaluable subjects, and it is
      desired that the same 24 subjects participate in all 3 study periods.

      Period 1 is an ascending single-dose study of TSX-011 at 3 doses, with the lowest dose
      administered under fed and fasted conditions: 190 mg TSX-011 in the fed state, 190 mg TSX-011
      in the fasted state, 380 mg TSX-011 in the fed state, and 570 mg TSX-011 in the fed state.
      Before exposure to TSX-011, a 24 hour baseline measurement of testosterone and DHT will be
      performed for each subject. Samples for analysis of testosterone will be obtained at the
      following time points on Day -1: hour 0 (8 am ± 60 minutes) and 1.5, 3, 4.5, 6, 8, 12, 16,
      and 24 hours (± 15 minutes for each time point).

      The day following the sampling for endogenous testosterone (Day 1) in Period 1, each subject
      will receive the first single dose of TSX-011 (190 mg) under fed conditions. Following
      administration of TSX-011, blood samples will be obtained over a 24-hour period for PK
      analysis. Subjects will undergo a minimum 3-day and up to 7-day washout period between each
      of the doses of TSX-011 in Period 1. After the 570 mg TSX 011 dose in Period 1, a minimum
      3-day and up to 7-day washout period will occur before the start of Period 2.

      Period 2 is a twice-daily dosing period, where fed subjects will be dosed with 380 mg TSX-011
      twice daily for 15 days (Days 1 through 15). Pharmacokinetic assessments over 24 hours will
      occur on Days 1 and 15. The TSX-011 dose will be titrated up or down beginning with the Day
      16 (Period 3) morning dose, based on established dosing rules.

      Period 3 is a dose-adjusted adaptive design period that begins on Day 16, with the first
      adjusted TSX-011 dose administered in the fed state on a once-daily or twice-daily schedule.
      The 6-hour postdose (± 15 minutes) testosterone level on Day 19 will be used to perform the
      second and final TSX-011 dose adjustment, based on established criteria. As specified by the
      dose adjustment rules, Day 26 begins with either a once-daily, twice-daily, or thrice-daily
      fed dose schedule. The thrice-daily dose schedule will be administered only to
      non-responders. On Day 30, a 24 hour PK assessment will be performed, and the subject's
      participation in the study is completed the morning of Day 31.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Incomplete effect
  </why_stopped>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">May 3, 2018</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants receive identical dosing for Period 1 and Period 2. Beginning with Period 3 subjects are assigned to one of several doses based on dose adjustments. Period 3 dosing groups are run in parallel for the duration of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders Based on Measured Total Testosterone (Cavg).</measure>
    <time_frame>Period 1: Up to 13 days. Period 2: 15 days. Period 3: 15 days.</time_frame>
    <description>TSX-011 responders are defined as study subjects who are able to achieve a Cavg serum total testosterone &gt; 350 ng/dL. The percentage of responders is recorded for each treatment group within each period.</description>
  </primary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Hypogonadism, Male</condition>
  <condition>Gonadal Disorders</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Testosterone Deficiency</condition>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 633 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 443 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 253 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalating Arm 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSX-011</intervention_name>
    <description>TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
    <arm_group_label>Dose-Escalating Arm 1</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 10</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 11</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 12</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 13</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 14</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 15</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 16</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 17</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 18</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 19</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 2</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 20</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 3</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 4</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 5</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 6</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 7</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 8</arm_group_label>
    <arm_group_label>Dose-Escalating Arm 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Testosterone level &lt;350 ng/dL, 10 am [± 2 hour] sample.

          -  Body mass index (BMI) &lt;35.0 kg/m2 and weight ≥50 kg

        Exclusion Criteria:

          -  History of clinically significant renal, hepatic, neurologic, hematologic, endocrine,
             oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other
             condition.

          -  Significant gastrointestinal or malabsorption conditions.

          -  Any man in whom testosterone therapy is contraindicated including the following:

               1. Known or suspected carcinoma (or history of carcinoma) of the prostate,
                  clinically significant symptoms of benign prostatic hyperplasia, and/or
                  clinically significant symptoms of lower urinary obstruction and International
                  Prostate Symptom Score (IPSS) ≥19. A clinically significant digital rectal
                  examination of the prostate or clinically significant elevated serum PSA levels
                  (&gt;4.0 ng/mL).

               2. Known or suspected carcinoma (or history of carcinoma) of the breast.

               3. Liver disease defined as alanine aminotransferase (ALT) or aspartate
                  aminotransferase (AST) &gt;2 × upper limit of normal (ULN) or bilirubin &gt;2 × ULN.

               4. Active deep vein thrombosis or thromboembolic disorder, or a documented history
                  of these conditions.

               5. Untreated sleep apnea.

               6. Hematocrit &gt;50%.

               7. Untreated moderate to severe depression.

          -  Current use of long-acting testosterone or any of the testosterone esters injectables.

          -  Topical, oral, or injectable testosterone replacement therapy.

          -  Clinically significant changes in any medications (including dosages) or medical
             conditions in the 28 days before screening.

          -  Suspected reversible hypogonadism (e.g., leuprolide injection).

          -  Taking concomitant medications that affect testosterone concentrations or metabolism

          -  Uncontrolled diabetes (screening glycated hemoglobin [HbA1c] ≥9%).

          -  Donated blood or blood products or experienced significant blood loss within 90 days
             before dosing.

          -  Donated bone marrow within 6 months before dosing.

          -  History of drug or alcohol abuse in the last 6 months.

          -  Ingested St John's wort within 30 days of screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Oefelein, MD</last_name>
    <role>Study Director</role>
    <affiliation>TesoRx Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <results_first_submitted>March 4, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2019</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Testosterone undecanoate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
    <mesh_term>Gonadal Disorders</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03335254/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03335254/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial enrolled nine male subjects. All subjects received treatment and completed the study. None of the enrolled/randomized subjects were withdrawn or discontinued from the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose-Escalating Arm 1</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P2">
          <title>Dose-Escalating Arm 2</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 633 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P3">
          <title>Dose-Escalating Arm 3</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P4">
          <title>Dose-Escalating Arm 4</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P5">
          <title>Dose-Escalating Arm 5</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P6">
          <title>Dose-Escalating Arm 6</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P7">
          <title>Dose-Escalating Arm 7</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P8">
          <title>Dose-Escalating Arm 8</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P9">
          <title>Dose-Escalating Arm 9</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P10">
          <title>Dose-Escalating Arm 10</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 443 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P11">
          <title>Dose-Escalating Arm 11</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P12">
          <title>Dose-Escalating Arm 12</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P13">
          <title>Dose-Escalating Arm 13</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P14">
          <title>Dose-Escalating Arm 14</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P15">
          <title>Dose-Escalating Arm 15</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P16">
          <title>Dose-Escalating Arm 16</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 253 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P17">
          <title>Dose-Escalating Arm 17</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P18">
          <title>Dose-Escalating Arm 18</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P19">
          <title>Dose-Escalating Arm 19</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="P20">
          <title>Dose-Escalating Arm 20</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, Day 1-15</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3, Day 16-25</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3, Day 26-30</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Under the same Period of the trial, only one dosing group was selected based on the adaptive dosing criteria. Therefore, some groups showed zero participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose-Escalating Arm 1</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dos 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B2">
          <title>Dose-Escalating Arm 2</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 633 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B3">
          <title>Dose-Escalating Arm 3</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B4">
          <title>Dose-Escalating Arm 4</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B5">
          <title>Dose-Escalating Arm 5</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B6">
          <title>Dose-Escalating Arm 6</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B7">
          <title>Dose-Escalating Arm 7</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B8">
          <title>Dose-Escalating Arm 8</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B9">
          <title>Dose-Escalating Arm 9</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B10">
          <title>Dose-Escalating Arm 10</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 443 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B11">
          <title>Dose-Escalating Arm 11</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B12">
          <title>Dose-Escalating Arm 12</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B13">
          <title>Dose-Escalating Arm 13</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B14">
          <title>Dose-Escalating Arm 14</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B15">
          <title>Dose-Escalating Arm 15</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B16">
          <title>Dose-Escalating Arm 16</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 253 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B17">
          <title>Dose-Escalating Arm 17</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B18">
          <title>Dose-Escalating Arm 18</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B19">
          <title>Dose-Escalating Arm 19</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B20">
          <title>Dose-Escalating Arm 20</title>
          <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="B21">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="0"/>
            <count group_id="B10" value="0"/>
            <count group_id="B11" value="0"/>
            <count group_id="B12" value="0"/>
            <count group_id="B13" value="0"/>
            <count group_id="B14" value="0"/>
            <count group_id="B15" value="0"/>
            <count group_id="B16" value="0"/>
            <count group_id="B17" value="0"/>
            <count group_id="B18" value="0"/>
            <count group_id="B19" value="0"/>
            <count group_id="B20" value="0"/>
            <count group_id="B21" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B21" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>yr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="6.66"/>
                    <measurement group_id="B21" value="51.9" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B21" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B21" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B21" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B21" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B21" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B21" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders Based on Measured Total Testosterone (Cavg).</title>
        <description>TSX-011 responders are defined as study subjects who are able to achieve a Cavg serum total testosterone &gt; 350 ng/dL. The percentage of responders is recorded for each treatment group within each period.</description>
        <time_frame>Period 1: Up to 13 days. Period 2: 15 days. Period 3: 15 days.</time_frame>
        <population>Arm 2 to Arm 20 have zero participants due to dose adjustment based on the total testosterone levels presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose-Escalating Arm 1</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O2">
            <title>Dose-Escalating Arm 2</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 633 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O3">
            <title>Dose-Escalating Arm 3</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O4">
            <title>Dose-Escalating Arm 4</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O5">
            <title>Dose-Escalating Arm 5</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O6">
            <title>Dose-Escalating Arm 6</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 507 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O7">
            <title>Dose-Escalating Arm 7</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O8">
            <title>Dose-Escalating Arm 8</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O9">
            <title>Dose-Escalating Arm 9</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O10">
            <title>Dose-Escalating Arm 10</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 443 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O11">
            <title>Dose-Escalating Arm 11</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O12">
            <title>Dose-Escalating Arm 12</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O13">
            <title>Dose-Escalating Arm 13</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O14">
            <title>Dose-Escalating Arm 14</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, increase dose to 380 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O15">
            <title>Dose-Escalating Arm 15</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O16">
            <title>Dose-Escalating Arm 16</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 253 mg TU twice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O17">
            <title>Dose-Escalating Arm 17</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O18">
            <title>Dose-Escalating Arm 18</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O19">
            <title>Dose-Escalating Arm 19</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
          <group group_id="O20">
            <title>Dose-Escalating Arm 20</title>
            <description>Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is &gt;800 ng/dL, decrease dose to 380 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders Based on Measured Total Testosterone (Cavg).</title>
          <description>TSX-011 responders are defined as study subjects who are able to achieve a Cavg serum total testosterone &gt; 350 ng/dL. The percentage of responders is recorded for each treatment group within each period.</description>
          <population>Arm 2 to Arm 20 have zero participants due to dose adjustment based on the total testosterone levels presented.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
                <count group_id="O17" value="0"/>
                <count group_id="O18" value="0"/>
                <count group_id="O19" value="0"/>
                <count group_id="O20" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 3, Day 15-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 3, Day 26-30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events presented were collected from 1 December 2017 (first subject Day 0) and 17 May 2018 (last subject visit).</time_frame>
      <desc>An adverse event is considered any untoward or unfavorable medical occurrence associated with the subject’s participation in the study. Subjects were asked an open question such as “How have you been feeling since you were last asked?” at all visits from Day 0 to Exit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Period 1: Single Dose</title>
          <description>Period 1. Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="E2">
          <title>Period 2: Twice Daily Dose</title>
          <description>380 mg TSX-011 twice daily dosing period of 15 days in fed conditions.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="E3">
          <title>Period 3, Day 16-25: Once Daily Dose</title>
          <description>If Period 2 Day 8 total testosterone is &gt;800 ng/dL, subjects randomized in a 1:1 ratio to receive:
Schedule A: 317 mg (TU) TSX-011 twice daily OR
Schedule B: 507 mg (TU) TSX-011 once daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="E4">
          <title>Period 3, Day 16-25: Twice Daily Dose</title>
          <description>If Period 2 Day 8 total testosterone is &lt;350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
If Period 2 Day 8 total testosterone is ≥350 ng/dL and &lt;500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
If Period 2 Day 8 total testosterone is &gt;800 ng/dL, randomize subjects in a 1:1 ratio to receive:
Schedule A: 317 mg (TU) TSX-011 twice daily OR
Schedule B: 507 mg (TU) TSX-011 once daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="E5">
          <title>Period 3, Day 26-30: Once Daily Dose</title>
          <description>If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL:
Dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
If Period 3, Day 19 total testosterone is &gt;800 ng/dL, decrease TSX-011 dose as follows: Dose adjust subjects on once-daily dosing from 507 mg TU daily to 380 mg TU daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
        <group group_id="E6">
          <title>Period 3, Day 26-30: Twice Daily Dose</title>
          <description>If Period 3 Day 19 total testosterone is ≥350 ng/dL and &lt;500 ng/dL:
Dose adjust subjects on twice daily dosing as follows:
If dose is 570 mg TU twice daily, increase to 633 mg TU twice daily.
If dose is 443 mg TU twice daily, increase to 507 mg TU twice daily.
If dose is 380 mg TU twice daily, increase to 443 mg TU twice daily.
If dose is 317 mg TU twice daily, increase to 380 mg TU twice daily. If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose twice daily.
If Period 3 Day 19 total testosterone is &gt;800 ng/dL, decrease TSX-011 dose as follows:
For the twice-daily dosing group:
If dose is 570 mg TU twice daily, decrease to 507 mg TU twice daily.
If dose is 443 mg TU twice daily, decrease to 380 mg TU twice daily.
If dose is 380 mg TU twice daily, decrease to 317 mg TU twice daily.
If dose is 317 mg TU twice daily, decrease to 253 mg TU twice daily. TSX-011 are capsules with primarily Testosterone Undecanoate.</description>
        </group>
        <group group_id="E7">
          <title>Period 3, Day 26-30: Thrice Daily Dose</title>
          <description>If Period 3 Day 19 total testosterone is &lt;350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever/Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Insect Bite/Arthropod Bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheaded/Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor will review and provide prior written consent, which shall not be unreasonably withheld.
PI will be permitted to publish in journals, theses, dissertations, or other formats of their own choosing.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Oefelein, MD, Chief Medical Officer</name_or_title>
      <organization>TesoRx Pharma, LLC</organization>
      <phone>909-595-0500 ext 104</phone>
      <email>karl@tesorx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

